Feedback
Settings

Settings

Goto Application

1. WO2020239953 - PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS

Submit observation
PermaLink
Publication Number WO/2020/239953
Publication Date 03.12.2020
International Application No. PCT/EP2020/064915
International Filing Date 28.05.2020
IPC
C07D 471/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 475/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
475Heterocyclic compounds containing pteridine ring systems
C07D 475/02 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
475Heterocyclic compounds containing pteridine ring systems
02with an oxygen atom directly attached in position 4
C07D 475/06 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
475Heterocyclic compounds containing pteridine ring systems
06with a nitrogen atom directly attached in position 4
A61P 11/06 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
06Antiasthmatics
A61P 11/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
14Antitussive agents
CPC
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61P 11/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
06Antiasthmatics
A61P 11/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
14Antitussive agents
C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 475/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
475Heterocyclic compounds containing pteridine ring systems
06with a nitrogen atom directly attached in position 4
Applicants
  • CHIESI FARMACEUTICI S.P.A. [IT]/[IT]
Inventors
  • BRUNO, Paolo
  • BIAGETTI, Matteo
  • FIORELLI, Claudio
  • BAKER-GLENN, Charles
  • VAN DE POËL, Hervè
  • PENROSE, Stephen, David
  • LANARO, Roberta
Priority Data
19177610.331.05.2019EP
19201165.802.10.2019EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS
(FR) DÉRIVÉS DE PYRIDOPYRIMIDINES UTILISÉS EN TANT QU'INHIBITEURS DE P2X3
Abstract
(EN) The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3 (hereinafter P2X3 inhibitors); particularly the invention relates to compounds that are pyridopyrimidines derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
(FR) La présente invention concerne des composés de formule I inhibant le purinorécepteur P2X 3 (ci-après désignés inhibiteurs de P2X3) ; en particulier, l'invention concerne des composés qui sont des dérivés de pyridopyrimidines, des procédés de préparation de tels composés, des compositions pharmaceutiques les contenant et leur utilisation thérapeutique. Les composés de l'invention peuvent être utiles dans le traitement de nombreux troubles associés aux mécanismes des récepteurs P2X3, tels que les maladies respiratoires comprenant la toux, l'asthme, la fibrose pulmonaire idiopathique (FPI) et la bronchopneumopathie chronique obstructive (BPCO).
Related patent documents
AU2020281924
BR112021020279
KR1020220016074
CN114222741
EP3976609
CA3136024
MXMX/a/2021/014116This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
JP2021571021This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
RU2021138377This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau
# -